Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Utility of Monitoring H3.1 Plasma Concentrations as a Surrogate of Treatment Response and Remission in Dogs with Cancer

Sunday, March 24, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster titled 'Utility of Monitoring H3.1 Plasma Concentrations as a Surrogate of Treatment Response and Remission in Dogs with Cancer' was presented by Dr. Heather Wilson-Robles and colleagues at the World Veterinary Cancer Congress 2024 in Tokyo. The study explores the use of H3.1 plasma levels as a potential indicator of treatment efficacy in canine cancer patients. This research could enhance monitoring strategies in veterinary oncology.
Price reaction · baseline $14.654 (2024-03-22 close) · 3 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study presents a novel approach to monitor treatment response.
  • It highlights the potential of H3.1 plasma concentrations in veterinary oncology.
  • The presentation at a significant conference indicates recognition in the field.

Full Press Release Details

Poster titled: ‘Utility of Monitoring H3.1 Plasma Concentrations as a Surrogate of Treatment Response and Remission in Dogs with Cancer’.
Presented at: World Veterinary Cancer Congress 2024, Tokyo 2024
Dr Heather Wilson-Robles et al
• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was the focus of the presented study?

The study focused on monitoring H3.1 plasma concentrations as a surrogate for treatment response in dogs with cancer.

Where was the study presented?

The study was presented at the World Veterinary Cancer Congress 2024 in Tokyo.

Who conducted the research?

The research was conducted by Dr. Heather Wilson-Robles and her team.

What is the significance of H3.1 plasma levels?

H3.1 plasma levels may serve as an indicator of treatment efficacy in canine cancer patients.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare canine cancer H3.1 plasma treatment response veterinary oncology
Last updated: Mar 24, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk